Management of hepatocellular carcinoma in the time of COVID-19

To the Editor,

We have read the paper by Zhang et al.1 reporting severe Coronavirus disease 2019 (COVID-19) in 28 cancer patients from China. Among these patients, there were two (7%) with hepatocellular carcinoma (HCC), who are at high risk of poor outcomes, if infected, according to age, comorbidities, and underlying cirrhosis. However, we should also consider the collateral damage it brings to the systems of care on which our patients depend, including interruption and delay in the schedule of HCC screening, treatments, and follow-up. Currently, Italy is facing the COVID-19 pandemic as are other Western countries, with clinical activities being reduced and postponed to minimize the risk of transmission and to have all health personnel involved in facing the emergency.

We agree that more intensive attention should be paid to patients with cancer during the COVID-19 crisis, both for reducing the risk of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection and ensuring appropriate cancer patient management programs. In our center, all HCC cases are managed according to European Association for the Study of the Liver (EASL) guidelines and the Barcelona Clinic Liver Cancer (BCLC) staging system based on discussion from multidisciplinary meetings.2,3 To tackle the COVID-19 crisis by reducing as low as possible the risk of patients’ exposure to SARS-CoV-2 and spreading of the infection within the hospital, we modified the management algorithm as follows:

- Telemedicine by video call has been preferred to face-to-face visits.
- The weekly multidisciplinary meetings are conducted by conference calls, sharing images online to reduce the risk for health-care operators without delaying decisions.
- Indications for liver transplantation (LT) have not changed, although management follows a recently published algorithm.4 In summary, we have reserved LT for patients with high risk of drop-out due to progression of HCC. This decision has been made not only because of the shortage of intensive care unit beds availability, but also following the dramatic reduction in the donor pool.
- Moreover, to reduce the risk of disease progression during the waiting period, we encouraged locoregional treatment (LRT) as bridge treatment to LT, whenever possible.
- The SARS-CoV-2 test is carried out in all patients 1 day before admission; only negative patients are admitted to dedicated rooms in our ward (to protect them against nosocomial SARS-CoV-2 infection). To ensure safety for both our patients and providers, protocols have been implemented to prepare the staff and angiographic suite before the arrival of patients, by optimizing the ventilation systems and intraprocedural plus postprocedural workflow.
- LRTs, such as microwave thermal ablation and radiofrequency thermal ablation (TA), are preferred to surgical resection to reduce both the needs of postoperative stays in the intensive care unit and hospitalization time, leaving surgery as a salvage option only in cases not achieving complete radiological response or not appropriate for LRTs.
- Palliative treatments, such as transarterial chemo(radio)embolization (TACE, TARE), are maintained, but postponed in the elderly (>80 years) and in patients with comorbidities, to minimize risk connected to hospitalization, weighing the oncological benefit versus the risk of exposure to SARS-CoV-2.
- The management of patients with advanced HCC treated with systemic drugs has been modified as well. Home blood sampling and drug delivery were implemented together with video calls to manage common adverse events. Intravenous anticancer therapies are dispensed in a dedicated section of our outpatient service.
- Imaging techniques carried out for diagnosis or staging are revised via the intranet, telemedicine, or after courier delivery. As far as patients who receive any treatment, radiological follow-up is scheduled as usual, but postponed up to 3 months in elderly patients and in those with comorbidities.

According to these modifications in our HCC management, we compared our performance between 24 February and 20 March 2020 with that in the same time frame in 2019 (Table 1). In summary, the HCC treatments for 42 patients were scheduled with a delay of ≥2 months in only 11 (26%) patients: two TA, four TACE, three TARE, and two systemic therapies. TAs were carried out instead of pre-planned surgical resection in three patients.

As the pandemic evolves, our approach to HCC management will be reviewed and our procedures updated. However, we believe that many of these changes implemented today to face this crisis will remain useful in managing any future emergencies.

M. Iavarone1*, A. Sangiovanni1, G. Carrafiello2, G. Rossi2,4 & P. Lampertico1,2

1Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC “A. M. and A. Migliavacca” Center for Liver Disease, Milan; 2Department of Pathophysiology and Transplantation, University of Milan, Milan;
Table 1. Management of HCC patients before and during COVID-19 emergency: a 4-week period in 2019 was compared with a 4-week period in 2020

| Management | 25 February to 22 March 2019 | 24 February to 20 March 2020 |
|------------|-------------------------------|-----------------------------|
| Outpatient visits, n | 117 77 a | 46 42 |
| Cases discussed in multidisciplinary meetings, n | 3 2 | 1 |
| Liver transplants for HCC, n | 3 1 | 4 7 |
| Surgical resections, n | 9 4 | 4 7 |
| MWTA and RFA, n | 47 | 1 |
| TACE, n | 94 | 1 |
| TARE, n | 31 | 1 |
| Total number of patients admitted to the ward | 58 48 | 2 |

MWTA, microwave thermal ablation; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.

a Week 1: 35 visits; week 2: 23 visits; week 3: 17 visits; and week 4: 2 visits.

REFERENCES
1. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31. https://doi.org/10.1016/j.annonc.2020.03.296.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
3. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
4. Gori A, Dondossola D, Antonelli B, et al. Coronavirus disease 2019 and transplantation: a view from the inside. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15853.
5. Ierardi AM, Wood BJ, Gaudino C, et al. How to handle a COVID-19 patient in the angiographic suite. Cardiovasc Intervent Radiol. 2020. https://doi.org/10.1007/s00270-020-02476-8.

FUNDING
None declared.

DISCLOSURE
MI: speaking and teaching: Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, Eisai; consultant: BTG-Boston Scientific, Bayer. AS: speaker Bureau: Bayer, Gilead Science, Janssen, BTG, Abb-Vie, Novartis; Advisory board: Tiziana Life Sciences. GC and GR: no conflicts of interest declared. PL: advisory board/speaker bureau for BMS, Roche, Gilead Sciences, GSK, AbbVie, MSD, Arrowhead, Alnylam, Janssen, Spring Bank, MYR, Eiger. GC, GR: no conflicts of interest declared.